Abbott India Reports on Business Responsibility and Sustainability for FY 2025-26

Abbott India Reports on Business Responsibility and Sustainability for FY 2025-26​

Abbott India Limited has completed its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, detailing its operations, commitment to responsible conduct, and ESG performance across various business aspects. The report outlines the company’s focus on affordable healthcare access, environmental stewardship, and workforce well-being within the pharmaceutical sector.

Operational Scope and Business Profile​

Abbott India Limited is a major player in the pharmaceuticals market, with 100% of its turnover derived from manufacturing, marketing, and distribution of pharmaceuticals. As of the end of FY 2025-26, the company had a total workforce of 3,467 employees, comprising 3,080 male and 387 female permanent employees. The organization operates across multiple locations, including plants and offices in Mumbai, Chembur, Chennai, Hyderabad, Lucknow, Delhi, Goa, and Nepal (excluding Nepal office for specific indicator reporting).

The company serves both national and international markets. Its operations span 28 Indian states and 8 Union territories. Exports constitute 1.2% of the total turnover. Stakeholder groups identified include patients, consumers, healthcare professionals, governments, suppliers, and employees.

ESG Performance Highlights​

The BRSR details a comprehensive overview of the company’s environmental and social responsibilities, with independent assurance provided by DNV Business Assurance India Private Limited for FY 2025-26.

Environmental Stewardship​

Abbott India has focused on reducing its climate impact and improving resource management across its operations. Key findings include:

• Energy Management: The Abbott India corporate office successfully reduced its Scope 2 emissions by 73% compared to the 2018 baseline. Operations utilize advanced energy-saving technologies, such as modular UPS and VRF systems in critical rooms at the server and UPS facility.
• GHG Emissions: Total Scope 1 emissions for FY 2025-26 stood at 155.39 MT of CO2 equivalent, while total Scope 2 emissions were 5,144.13 MT of CO2 equivalent. The combined intensity was 0.76 MT of CO2e per crore INR.
• Water Management: Total water consumption for the period was 65,602.43 KL. Water discharge to third parties totaled 864.07 KL.
• Waste Management: The company maintains a commitment to Zero Waste-to-Landfill (ZWL) at its BKC and Goa plant facilities. Total waste generated stood at 662.86 MT, with recovery through recycling, re-use, or other recovery operations totaling 627.42 MT, achieving a recovery rate of 94.65%.

Social Responsibility and Workforce​

The report detailed numerous initiatives focused on enhancing employee well-being and advancing healthcare access in the community:

• Employee Welfare: Abbott implemented comprehensive programs such as 'BeStrong,' which covers physical (FitStrong), mental/emotional (MindStrong), financial (WealthStrong), and social wellness (BondStrong). The company also provides an Employee Assistance Program (EAP) with 24/7 availability for employees and their families.
• Gender Diversity: Within the Board of Directors, there were 3 female members out of 9, representing 33.33%. For Key Management Personnel, 2 out of 3 held a female role, achieving 66.67%. The gross wages paid to females totaled 12% of the company's total wages in FY 2025-26.
• Human Rights & Fairness: The company maintains policies against bribery and corruption. A dedicated Grievance Redressal Policy is maintained, allowing employees access through a 'Speak Up' portal and an Ethics and Compliance Helpline.
• CSR Initiatives: Abbott India committed to the upgradation of Primary Health Centres (PHCs) across 12 states in collaboration with Americares India Foundation. By the end of FY 2025-26, they had supported 209 PHC upgrades. Furthermore, over 4,50,000 people were screened for liver health and approximately 9,50,000 individuals were screened for thyroid conditions across various states.

Innovation and Customer Focus​

The company leveraged innovation to address therapeutic barriers. Key product launches during the year included Extensior (semaglutide), an innovative therapy for Type 2 Diabetes developed through a partnership with Novo Nordisk, and Ezybixy (elobixibat) for chronic constipation. The launch of these therapies underscores Abbott India's commitment to advancing metabolic care and removing access barriers in India.

In terms of customer relationship management, the company recorded 342 complaints from customers received during FY 2025-26, with 66 pending resolution at year end. The company maintains a policy on Cyber-security and risks related to data privacy.

Governance and Oversight​

Kartik Rajendran, Managing Director, and Kartik Rajendran, who serves as the designated authority for the Business Responsibility report, oversee the implementation of the policies.

The overall performance indicators tracked across various metrics include:


The company also reports a commitment to working with local suppliers, sourcing inputs from MSMEs/Small Producers at a rate of 22.19%.

ABBOTINDIA Stock Price Movement​

Today, Abbott India Limited shares edged higher to settle at ₹28275, gaining 0.73% as trading closed for the day. The stock finished with a total traded volume of 8,865 shares.